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Introduction
Breast cancer is the most frequently encountered
malignant disease in women and provides a challenging
daily problem for doctors, patients and healthcare systems
in the western world. The incidence rate of this malig-
nancy is rising steadily and in Germany 1 of 9 women
will have breast cancer. In the USA the comparable figure
is 1 in 8 women. An optimistic outcome requires diagnosis
in its early stages. Many patients receive radiotherapy,
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It is essential for physicians and surgeons who are involved in the treatment of breast cancer to develop a better appreciation
of the problems encountered when radiation therapy is given. In this brief review special emphasis is placed on treatment toxicity
and patient quality of life and on the assessment of treatment success.
The aim of radiation therapy (RT) is local recurrence prevention. With the introduction of RT after breast conserving surgery
the local recurrence rate fell from 25-40% to the current rates of 6-8%. In developing countries, such as Tunesia, the rate may
be as high as 15% due to 60Co – teletherapy without the use of a treatment planning system as well as with the initial
advanced stage of the disease in those countries.
An important additional endpoint of treatment is the quality of life and long-term toxicity. Severe deterioration of RT toxicity
is caused by intramammarian seromas and extended tissue defects, certain concomitant chemotherapy protocols and the
deliberate use of parasternal lymph node irradiation. Age, however, does not influence the radiogenic toxicity.
We conclude that apart from local control and five-year survival these additional endpoints, i.e. defining toxicity and quality
of life, have to be accepted by all physicians involved in breast cancer treatment.
Ryzyko zwiàzane z leczeniem raka piersi ze szczególnym uwzgl´dnieniem sytuacji w krajach rozwijajàcych si´
Lekarze zaanga˝owani w proces leczenia chorych z rakiem piersi muszà zdawaç sobie spraw´ z problemów wynikajàcych ze
stosowania radioterapii. W niniejszej pracy przedstawiono pokrótce zagadnienia zwiàzane z wp∏ywem odczynów po
napromienianiu oraz jakoÊci ˝ycia na ogólnà ocen´ wyników leczenia.
Radioterapia (RT) ma na celu zapobieganie wznowom miejscowym. Wprowadzenie radioterapii jako uzupe∏nienia leczenia
oszcz´dzajàcego pozwoli∏o zmniejszyç odsetek wznów miejscowych z 25-40% do 6-8%. Niemniej w paƒstwach rozwijajàcych
si´, takich jak Tunezja, odsetek ten si´ga nawet 15% ze wzgl´du na stosowanie teleterapii z u˝yciem kobaltu 60Co
z pomini´ciem jakichkolwiek technik planowania, jak równie˝ ze wzgl´du na znaczne zaawansowanie choroby w momencie
rozpoznania.
Dodatkowe istotne elementy rzutujàce na ocen´ wyników leczenia to jakoÊç ˝ycia i obecnoÊç póênych odczynów po radioterapii.
Te ostatnie nasilajà si´ znamiennie w sytuacji miejscowego gromadzenia si´ p∏ynu surowiczego w piersi, przy wspó∏istnieniu
rozleg∏ych ubytków tkankowych, w po∏àczeniu z jednoczasowym stosowaniem niektórych rodzajów chemioterapii oraz
w razie planowego naÊwietlania przymostkowych w´z∏ów ch∏onnych. Stwierdzono, ˝e wiek chorych nie wià˝e si´ z nasileniem
toksycznoÊci radioterapii.
Podsumowujàc mo˝na stwierdziç, ˝e w ocenie wyników leczenia raka piersi nale˝y braç pod uwag´ nie tylko wyleczenie
miejscowe i prze˝ycia pi´cioletnie, ale równie˝ póêne odczyny po napromienianiu i jakoÊç ˝ycia chorych.
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either alone or in combination with chemotherapy and/or
surgery, and thus the knowledge of risk factors associated
with radiation therapy is important. This paper also
emphasises the continuing wide differences between
developed and developing countries, and reviews the
recent experience of one of us [JS] on an IAEA radiation
oncology expert mission to Tunisia.
Epidemiology
I n c i d e n c e
Breast cancer is predominantly a problem in the
developed world (Table I), and the number of patients
in South America, Africa or South East Asia is much
lower than in Europe and the USA.
Table I. Average annual age-standardised (world) incidence rates
(ASR) per 100,000 for the registration period 1993-97 for selected
registry populations [1]; incidence rates for comparison, for prostate
and breast cancers. It is seen that even for developed countries with
a smaller incidence of prostate cancer, the breast cancer rates are still
high in the range 75-95 per 100,000 females
Registry ASR per 100,000 population
Prostate Breast
USA, SEER registries 107.0 92.1
Canada 80.2 78.5
Denmark 29.9 81.3
Netherlands 53.9 85.6
England, UK 39.6 74.4
Algeria, Algiers 5.4 21.3
Zimbabwe, Harare 30.7 20.3
Argentina, Concordia 31.3 55.1
Colombia, Cali 42.2 37.3
Thailand, Bangkok 6.8 25.5
Vietnam, Ho Chi Minh City 3.8 13.6
M i g r a t i o n
Migration of women from regions in South America,
Africa and South East Asia to northern developed
countries changes the originally lower risk dramatically –
equalling the figures in the native developed populations
within five years: according to the findings of the World
Health Organization [2]. Thus, the style of living, eating
habits, use of drugs or life’s stress might have a decisive
role in the development of breast cancer.
S o c i o e c o n o m i c  s t a t u s
On the other hand, the figures for breast cancer may
serve as an indicator for a population‘s socioeconomic
progress. Recent epidemiological data from the
Maghrebinian Republic of Tunisia have demonstrated
that a change towards a more westernised lifestyle
influences breast cancer incidence in younger women.
This data is now comparable with those of the southern
European country of Portugal.
S c r e e n i n g  a n d  e a r l y  d i a g n o s i s
Large differences remain in the healthcare systems and
the health education of the populations of Western
Europe and of North African countries. For example,
with elaborate breast cancer screening programs with
serial mammography studies the average tumour
diameter at diagnosis in Germany is 1.1 cm, while the
comparable figure in Tunisia is 5.1 cm. This leads to
a drastically inferior prognosis. At a tumour diameter of
1 cm about 25% of the patients are already affected by
subclinical metastatic spread of the disease whilst at 5 cm
nearly all the patients are suffering from distant, clinical
or subclinical metastases resulting in a very poor five-
year prognosis.
Role of radiation therapy
The role of radiation therapy is directed primarily towards
local control of the disease, with systemic treatments such
as chemotherapy and hormonal therapy given to enhance
the 5-year or 10-year survival rates. In the early days of
breast conserving surgery without radiotherapy, local
recurrence rates were in the range 25-40%. After the
introduction of postsurgical radiotherapy to the entire
remaining breast tissue these figures fell to the current
rates of 6-8%. Hence the quality of radiation therapy in
terms of equipment and treatment planning can be
measured by the evaluation of the local recurrence rates.
On a recent expert mission to Tunisia for the IAEA,
one of us [JS] found that the local recurrence rate in
radiotherapy was one of the decisive factors used to
evaluate the quality of treatment. Whilst the recurrence
rate in Kiel is 3%, in one of the Tunisian institutions
visited, the local recurrence rate after breast conserving
treatment and radiotherapy was as high as 15%. It was
then determined that treatment by 60Cobalt teletherapy
without any use of a treatment planning system, as well as
the advanced stage of disease, was the determining factor
for this unsatisfactory result.
Risk factors
Local control is not the sole endpoint assessment
following radiation therapy for breast cancer. In this
primarily curative treatment, long-term toxicity and
quality of life are of major interest. This is not always
well recognized in developed countries, as a consequence
of inferior treatment results. Also, perhaps due to the
fact that all individual specialists playing a part in breast
cancer treatment modalities, do not have sufficient
knowledge of risk factors relating to treatment.
In a classical interdisciplinary treatment for breast
cancer the results of radiation therapy depend upon the
skills of the gynaecologist, the medical oncologist, the
radiologist and also the general practitioner. To enhance
their knowledge the risk factors associated with radiation
oncology must be known.
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S e r o m a s  a n d  t i s s u e  d e f e c t s
A total of 104 consecutive patients with breast conserving
treatment were irradiated in Kiel. The techniques were
planned individually based on a CT dataset. All the
acquired slices were evaluated with regard to seromas,
larger tissue defects or organized hematomas exposing
risk factors for radiation therapy.
In 38/104 patients, seromas and tissue defects
measuring more than 2 cm were detected. 21/38 had
already complained of discomfort in the breast and scar
induration prior to radiation therapy. Thereafter, 36/38
patients had similar symptoms. 23/38 rated the cosmetic
result worse than immediately after sugery. Of 66/104
patients without drainage problems only 9/66 had
symptoms and only 4/66 rated the cosmetic result as
worse.
We conclude that seromas and tissue defects after
breast conserving carcinoma treatment increase the rate
of side-effects during radiation therapy and lead to
deterioration of the cosmetic results.
Pre-therapeutic applied CT allows to puncture
hidden seromas and provides individual adaptation of
the irradiation technique so as to avoid overdosage caused
by tissue defects. Therefore, CT should be performed on
all patients prior to radiation therapy and surgeons should
continue to drain the resection hole and the axilla,
preferably with active suction [3-5].
A g e
Cancer in elderly patients is frequently treated below
standards. Arguments for such a strategy include poor
prognosis, higher toxicity and costs. Therefore, in Kiel
we have evaluated the standards of treatment in elderly
women with breast cancer and assessed the results of
their radiation therapy. Of the 218 consecutively treated
breast cancer patients 83/218 were older than 64 years.
Their 5-year survival rate was 77.1% and their rate of
local recurrence was 1.2%. No significant age group
specific differences in surgical and radiotherapy treatment
and in toxicity could be found.
We therefore conclude that the prescription of
curative treatment is independent of age and should be
given to elderly as well as younger patients. A policy of
discriminating the elderly is by no means justified [6].
S y s t e m i c  t r e a t m e n t
In general, the combination modality of radiochemo-
therapy is well tolerated and does not cause major
problems. For the radiation oncologist however, gemci-
tabine and anthracyclines pose a certain risk. Whilst
anthracyclines elevate the skin toxicity and can sometimes
lead to severe erythema in grade 3-4, the concurrent
application of gemcitabine and radiation therapy might
lead to severe general toxicity. In the most severe cases
this may cause sudden death [7]. Thus, as a precaution,
radiotherapy should never be applied regularly together
with these agents except within controlled clinical
trials [8].
Pa r a s t e r n a l  l y m p h n o d e  i r r a d i a t i o n
In former times radiation oncologists used to treat the
parasternal lymph node chain with single fields of 6 MV
or 60Cobalt photons. However they underrated the toxicity
of such a treatment to the heart and to the coronary
arteries and also overrated its therapeutic benefit. All
institutions now continuing such a protocol should
urgently revise their strategy. It is now common belief
that irradiation of the parasternal lymph nodes is only
necessary in selected cases at risk and that the long-term
toxicity at the heart by far surpasses the therapeutic
benefit [9].
Conclusions
As well as the accepted treatment endpoints, such as local
control and five-year survival rate, additional endpoints
are needed which define toxicity and quality of life.
Methods to measure the individual quality of life and the
influence of late toxicity of treatment are available and
have been applied in controlled trials [10]. These will
enhance our ability to measure the treatment sequelae
not only in a curative setting, but for assessment of
treatment in a palliative setting [11].
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